Obesity and type 2 diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 4, 2003, Pages 805-822

  Maggio, Carol A ^a   Pi Sunyer, F Xavier ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOUNSATURATED FATTY ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; SATURATED FATTY ACID; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ANOREXIA; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ROUX Y ANASTOMOSIS; SATIETY; STOMACH BYPASS; TACHYCARDIA; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0347993840     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(03)00071-9     Document Type: Review

References (82)

1. American Diabetes Association. Diabetes facts and figures. Available at: www.diabetes. org. Accessed December 31, 2002.
2. Albu J, Pi-Sunyer FX. Obesity and diabetes. In: Bray GA, Bouchard C, James WPT, editors. Handbook of obesity. New York: Marcel Dekker; 1998. p. 697-707.
3. Rewers M, Hamman RF. Risk factors for non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, editors. Diabetes in America. 2nd edition. Washington, DC: US Government Printing Office; 1995. p. 179-220.
4. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-9.
5. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23:1278-83.
6. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab 2002;15(Suppl 2):737-44.
7. West KM, Kalbfleish. Glucose tolerance, nutrition and diabetes in Uruguay, Venezuela, Malaya and East Pakistan. Diabetes 1966;15:9-18.
8. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345(11):790-7.
9. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523-9.
10. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997;146:214-22.
11. Colditz GA, Willet WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-13.
12. Holbrook TL, Barrett-Connor E, Wingard DL. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obes 1989;13:723-9.
13. Everhart JE, Pettitt DJ, Bennett PH, Knowler WC. Duration of obesity increases incidence of NIDDM. Diabetes 1992;41:235-40.
14. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, et al. The influence of body fat distribution on the incidence of diabetes mellitus. Diabetes 1985;34:1055-8.
15. Lundgren H, Bengtsson C, Blohme G, Lapidus L, Sjostrom L. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: results from a prospective population study in Gothenburg, Sweden. Int J Obes 1989;13:413-23.
16. Haffner SM, Stern MP, Hazuda HP, Pugh J, Patterson JK. Do upper-body and centralized adiposity measure different aspects of regional body-fat distribution? Diabetes 1987;36:43-51.
17. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes. A prospective study among Japanese Americans. Diabetes Care 2000;23:465-71.
18. De Fronzo RA. The triumvirate; B cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:644-67.
19. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
20. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
21. Olefsky JM, Kolterman OG, Scarlett JA. Insulin action and resistance in obesity and noninsulin-dependent type 2 diabetes mellitus. Am J Physiol 1982;243:E15-30.
22. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care Clin Office Pract 2003;30:465-91.
23. Van Itallie TB. Obesity: adverse effects on health and longevity. Am J Clin Nutr 1979;32:2723-33.
24. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
25. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563-76.
26. Blackburn GL, Read JL, Benefits of reducing revisited. Postgrad Med 1984;60:13-8.
27. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986;35:990-8.
28. Amatruda JM, Richeson JF, Well SL, Brodows RG, Lockwood DH. The safety and efficacy of a controlled low-energy ('very-low-calorie') diet in the treatment of non-insulin-dependent diabetes and obesity. Arch Intern Med 1988;148:873-7.
29. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type 2 diabetic patients. Metabolism 1990;39:905-12.
30. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type 2 diabetic patients. Arch Intern Med 1987;147:1749-53.
31. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992;16:397-15.
32. Watts NB, Spanheimer RG, DiGirolamo M, Gebhart SSP, Musey VC, Siddiq K, et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1991;150:803-6.
33. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991;14:802-23.
34. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;77:1287-93.
35. Gumbiner R, Polonsky KS, Beltz WF, Griver K, Wallace P, Brechter G, et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1990;70:1594-603.
36. Laakso M, Uusitupa M, Takala J, Majander H, Reijonen T, Penttila I. Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects. Metabolism 1988;37:1092-100.
37. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002;25:358-63.
38. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br J Med 1984;289:1257-61.
39. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year Follow up of participants in the study of men born in 1913. Br J Med 1984;288:1401-4.
40. Markovic TP, Campbell LV, Balasubramanian S, Jenkins AB, Fleury AC, Simons LA, et al. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care 1998;21:695-700.
41. Markovic TP, Jenkins AB, Campbell LV, Furler SM, Kraegen EW, Chisholm DJ. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998;21:687-94.
42. Pascale RW, Wing RR, Blair EH, Harvey JR, Guare JC. The effect of weight loss on change in waist-to-hip ratio in patients with type 2 diabetes. Int J Obes 1991;16:59-65.
43. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94.
44. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-41.
45. Uusitupa MI, Laakso M, Sarlund H, Majander H, Takala J, Penttila I. Effects of a very low-calorie diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin-dependent diabetics. Am J Clin Nutr 1990;51:768-73.
46. National Institutes of Health consensus development conference statement: health implications of obesity: Ann Intern Med 1985;103:1073-7.
47. MacDonald KG, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:213-20.
48. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.
49. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(Suppl 2):51S-210S.
50. Wadden TA. Treatment of obesity by moderate and severe caloric restriction: results of clinical research trials. Ann Intern Med 1993;119:688-93.
51. West KM. Diet therapy of diabetes: an analysis of failure. Ann Intern Med 1973;79:425-34.
52. Hadden DR, Blair ALT, Wilson EZ, Boyle DM, Atkinson B, Kennedy AL, et al. Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy. Q J Med 1986;59:579-98.
53. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. JAMA 1995;332:621-8.
54. Eckel RH, Yost TJ. Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women. J Clin Invest 1987;80:992-7.
55. Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL. Is the energy homeostasis system inherently biased toward weight gain? Diabetes 2003;52:232-8.
56. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003;26(Suppl 1):S51-61.
57. National Institutes of Health. Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus. Diabetes Care 1987;10:639-44.
58. Pi-Sunyer FX, Maggio CA, McCarron DA, Reusser ME, Stern JS, Haynes RB, et al. Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes. Diabetes Care 1999;22:191-7.
59. Heilbronn LK, Noakes M, Clifton PM. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes. Diabetes Care 1999;22:889-95.
60. Luscombe ND, Clifton PM, Noakes M, Parker B, Wittert G. Effects of energy-restricted diets containing increased protein on weight loss, resting energy expenditure, and the thermic effect of feeding in type 2 diabetes. Diabetes Care 2002;25:652-7.
61. Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care 1996;19:613-24.
62. The National Task Force on the Prevention and Treatment of Obesity. Very low-calorie diets. JAMA 1993;270:967-74.
63. Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type 2 diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994;97:354-62.
64. Hamby S, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001;30(4):883-907.
65. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus. A meta-analysis of controlled clinical trials. JAMA 2001;286:1218-27.
66. Wing RR, Epstein LH, Paternostro-Bayles M, Kriska A, Nowalk MP, Gooding W. Exercise in a behavioral weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1988;31:902-9.
67. Wing RR. Behavioral treatment of obesity: its application to type 2 diabetes. Diabetes Care 1993;16:193-9.
68. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998;56:1093-124.
69. McNulty SJ, Ur E, Williams G. for the Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-31.
70. Keating GM, Jarvis B. Orlistat in the prevention and treatment of type 2 diabetes mellitus. Drugs 2001;61:2107-19.
71. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8.
72. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3853-60.
73. Van Dijk G, Thiele TE. Glucagon-like-peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides 1999;33:406-14.
74. Gastrointestinal surgery for severe obesity National Institutes of Health consensus development conference statement 1991, March 25-27. Am J Clin Nutr 1992;55:615S-9S.
75. Jones KB. Experience with the Roux-en-Y gastric bypass, and commentary on current trends. Obes Surg 2000;10:183-5.
76. Albrecht RJ, Poires WJ. Surgical intervention for the severely obese. Baillieres Clin Endocrinol Metab 1999;13:149-72.
77. Poires WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-52.
78. Byrne TK. Complications of surgery for obesity. Surg Clin North Am 2001;81(5):1181-93.
79. Eriksson K-F, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991;34:891-8.
80. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing 1GT and Diabetes Study. Diabetes Care 1997;20(4):537-44.
81. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen J, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50.
82. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.